Thanks for your thoughts, Mark...
<<The mere mention of DMSO and people began walking the other way>>.
This is understandable, as DMSO is a solvent which, I believe, has never been approved for this purpose.
<<Re: Trials
In some people, DMSO can leave a slight taste in one's mouth, so doing a double blind placebo controlled study was made much more difficult - some would know immediately who was getting Pennsaid and the placebo - hence the rather lengthy phase IV study involving (to date) 3000 + subjects.>>
True, DMSO can leave an aftertaste in some people, however, my issue was not so much that they didn't do the double-blind, comparative trials, but also the fact that they don't have a lot of patient numbers to support their submission.
Having said all this, the fact that DMX has got this far has to provide a certain amount of comfort. Comparing DMX to other companies, once approval is finally given, I think it's an easy $20-$30 stock price, provided management doesn't mess up.
Regards,
Jeff
|
